U.S. lawmakers ramp up scrutiny of FDA following agency’s approval of controversial Alzheimer’s drug
By
Alicia Lasek
Sep 07, 2021
The FDA is being asked to help explain how Aduhelm (aducanumab) met accelerated approval criteria when so many experts — including internal advisers — have flagged insufficient safety and efficacy...
To save itself, might Medicare deny coverage of controversial new Alzheimer’s drug?
By
Kimberly Marselas
Jun 28, 2021
The true price to administer aducanumab — a controversial new Alzheimer’s treatment — may actually be closer to $100,000 annually than other, lower estimates and is just one reason the Centers for...